This CPB is revised to state that bendamustine is considered medically necessary for the following indications: 1) histologic transformation of marginal zone lymphoma to diffuse large B-Cell lymphoma, with or without rituximab after multiple lines of chemoimmunotherapy for indolent or transformed disease ; 2) nodal peripheral T-cell lymphoma with TFH phenotype, as second-line or subsequent therapy as a single agent for relapsed or refractory disease; 3) follicular T-cell lymphoma, as second-line or subsequent therapy as a single agent for relapsed or refractory disease; 4) post-transplant lymphoproliferative disorders, as second-line and subsequent therapy with or without rituximab for patients with partial response, persistent or progressive disease after receiving chemoimmunotherapy as first-line treatment for monomorphic PTLD (B-cell type), This CPB is revised to state that bendamustine for classical Hodgkin's lymphoma is considered medically necessary as second-line or subsequent systemic therapy for relapsed or refractory disease as a component of gemcitabine/bendamustine/vinorelbine ± brentuximab vedotin, This CPB is revised to state that bendamustine for diffuse large B-cell lymphoma is considered medically necessary as second-line or subsequent therapy with or without rituximab for relapsed or refractory disease in noncandidates for high-dose therapy. This CPB is revised to state that bendamustine for mantle cell lymphoma is considered medically necessary as a component of RBAC (rituximab, bendamustine, and cytarabine) regimen. This CPB is revised to state that bendamustine for mycosis fungoides/Sezary syndrome is considered medically necessary with or without skin-directed therapies or radiotherapy. This CPB is revised to remove primary cutaneous B-cell lymphoma as a medically necessary indication for bendamustine. This CPB has been revised to state that bendamustine is considered experimental and investigational for systemic light-chain (AL) amyloidosis.